Related Experiment Video
Updated: Oct 5, 2025
10:16
Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
Published on: August 17, 2022
3.5K
COVID vaccines: then and now
1Chief Nurse, Oxford University Hospitals.
British Journal of Nursing (Mark Allen Publishing)
|January 31, 2022
Summary
Early vaccine uptake saw large crowds, but a year later, many were reluctant to get vaccinated. This highlights a shift in public perception and behavior towards immunizations.
Area of Science:
- Healthcare Management
- Public Health Policy
- Nursing Leadership
Background:
- Initial COVID-19 vaccination campaigns in early 2021 saw unprecedented public engagement.
- A notable decrease in enthusiasm and increased hesitancy were observed among certain populations by early 2022.
Purpose of the Study:
- To analyze the contrasting public response to COVID-19 vaccination drives over a one-year period.
- To identify potential factors contributing to vaccine hesitancy in later stages of the pandemic.
Main Methods:
- Qualitative reflection by a Chief Nurse at Oxford University Hospitals.
- Observational analysis of vaccination center attendance.
- Comparative assessment of public engagement in 2021 versus 2022.
Main Results:
- Significant difference in crowd sizes and public eagerness between the initial mass vaccination phase and the subsequent period.
- Emergence of 'reluctant latecomers' indicating a shift in vaccine acceptance dynamics.
Conclusions:
- The initial surge in vaccination demonstrated strong public trust and urgency.
- Subsequent vaccine hesitancy suggests a need for evolving public health strategies to address changing attitudes and concerns.
Related Concept Videos
01:51Vaccinations
45.6K
Overview
45.6K
01:30Cancer Vaccines
545
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
545
00:36Viral Mutations
34.4K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
34.4K
01:11Clinical Trials: Overview
3.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K
01:29Microorganisms in Medicine and Therapeutics
450
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
450
01:22Development of Immunocompetence
485
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
485